Academic & Start-up Company Partnerships
Pfizer currently supports numerous collaborative partnerships with world-class research institutions such as the University of California, the Scripps Research Institute, the University of Pennsylvania, the University of Hong Kong, Peking University, and the Shanghai Institute for Biological Sciences, among many others, and is seeking additional opportunities to identify seed-stage investment opportunities to support early-stage technologies as they transition from a pure academic environment into new start-up companies that align with our core research interests. These investments complement our Pfizer Venture Investment activities.
Alternative Development / Funding Models
Pfizer WRD is actively exploring risk and cost sharing approaches to develop WRD as well as external partner programs to enable promising therapies to reach patients. Approaches include partnering WRD assets with pre-defined buy back rights, leveraging non-dilutive funding, and establishing strategic disease area alliances with biopharmaceutical companies and private equity / venture capital groups. Partnerships across the full range of WRD disease areas of interest, which are described in this brochure, will be considered, with a focus on clinical stage programs in particular.
Alternative Development / Funding Models Contact:
Girish Aakalu (Girish.N.Aakalu@pfizer.com)
Centers for Therapeutic Innovation
The Centers for Therapeutic Innovation (CTI) labs were created to establish real-time research partnerships with select academic medical centers. CTI academic research partners work side-by-side with Pfizer scientists in the discovery and development of new therapies for unmet medical needs. Pfizer has opened new CTI labs in San Francisco, New York, Boston, and San Diego. These state-of-the-art laboratories are populated with Pfizer scientists and post-docs exploring opportunities to advance novel antibody therapeutics through preclinical development and first-in-human proof of mechanism studies. Pfizer's Centers for Therapeutic Innovation demonstrate the company's deep commitment to establishing close partnerships with leading academic medical centers to translate ground-breaking research into important new therapies that address key unmet medical needs.
Tony Coyle (Anthony.Coyle@pfizer.com)
External Research Units
Pfizer WRD has recently established a virtual biotech model, termed the 'External Research Units,' to develop portfolios in a fast and flexible fashion. This is accomplished through a network of external partnerships through which external scientists interface with a small core group of Pfizer experts in the given indication area. This highly collaborative mechanism allows for rapid investments in fields that are strategically important and complementary to Pfizer's WRD and Business Unit organizations. Already, this model has been applied to address fibroproliferative disease, hematology and immunoregulation. Partnering opportunities of highest interest will be at the CAN-PoC through Phase 2 stage of development.
External Research Units Contact
Karim Dabbagh (Karim.Dabbagh@pfizer.com)
Joachim Fruebis (Joachim.Fruebis@pfizer.com)
Barbara Sosnowski (Barbara.Sosnowski@pfizer.com)
— Fibroproliferative Disease
Pfizer Venture Investments (PVI)
Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, invests in private companies in traditional venture capital syndicates. PVI also uses equity to support novel business structures such as consortium-based technology development (e.g. Ablexis), product out-licensing (e.g. Clovis Oncology) and business spinouts (e.g. Ziarco). Further, PVI invests in funds that offer geographic reach to provide a view into the development of healthcare and life sciences businesses in developing countries such as Africa, Brazil and China. PVI has an interest in working with others to explore new business models that can create value for all players in the healthcare/life sciences ecosystem and ensure the continued development of therapeutics, technologies and services for all those whose medical needs are not being met.
Please visit www.pfizerventureinvestments.com
Barbara Dalton (Barbara.Dalton@pfizer.com)
Strategic Research Partnerships (SRP)
The Strategic Research Partnerships team is composed of skilled scientists with pharmaceutical and biotechnology research experience, all working to support Pfizer's global research interests by scouting for collaborative relationships with both academic and biopharmaceutical partners. These scientists are deployed globally to ensure Pfizer is an active participant in regional scientific discussions and help us work closely with our partners once relationships are established. By working with our 100+ Pfizer country organizations, we have built a strong international scouting network capable of connecting our R&D scientists to innovative opportunities around the world.
The Strategic Research Partnerships group also drives the activities of the Pfizer Global Incubator, a seed-stage investment fund available to support collaborations with start-up companies founded by experienced entrepreneurs pursuing the commercialization of their inventions for the benefit of patients.
Key Regional Contacts:
Yuan-Hua Ding (Yuan-Hua.Ding@pfizer.com)
Peter Luke (Peter.Luke@pfizer.com)
Australia / NZ
Dan Grant (Daniel.Grant@pfizer.com)
Bettina Hamelin (Bettina.Hamelin@pfizer.com)
Mark Lundie (Mark.Lundie@pfizer.com)
Patrice Roy (Patrice.Roy@pfizer.com)
Nessa Carey (Nessa.Carey@pfizer.com)
James Eshelby (James.Eshelby@pfizer.com)
Maria Flocco (Maria.Flocco@pfizer.com)
Ajith Kamath (Ajith.V.Kamath@pfizer.com)
Olga Krylova (Olga.Krylova@pfizer.com)
Gabriela Cezar (Gabriela.G.Cezar@pfizer.com)
Olga Krylova (Olga.Krylova@pfizer.com)
Melissa Fitzgerald (Melissamarie.Fitzgerald@pfizer.com)
Greg Naeve (Gregory.Naeve@pfizer.com)
Jeff Southerton (Jeff.Southerton@pfizer.com)